101 related articles for article (PubMed ID: 16307454)
21. Predictivity of standardized and controlled permeation studies: Ex vivo - In vitro - In vivo correlation for sublingual absorption of propranolol.
Majid H; Bartel A; Burckhardt BB
Eur J Pharm Biopharm; 2021 Dec; 169():12-19. PubMed ID: 34508807
[TBL] [Abstract][Full Text] [Related]
22. A case for sublingual captopril.
Belz GG; De Mey C
Blood Press; 1992 Aug; 1(2):120-2. PubMed ID: 1366260
[No Abstract] [Full Text] [Related]
23. Exercise and the pharmacokinetics of propranolol, verapamil and atenolol.
van Baak MA; Mooij JM; Schiffers PM
Eur J Clin Pharmacol; 1992; 43(5):547-50. PubMed ID: 1483493
[TBL] [Abstract][Full Text] [Related]
24. Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat.
Laethem ME; Belpaire FM; Wijnant P; Rosseel MT; Bogaert MG
Chirality; 1994; 6(5):405-10. PubMed ID: 8068500
[TBL] [Abstract][Full Text] [Related]
25. Characterization of captopril sublingual permeation: determination of preferred routes and mechanisms.
Chetty DJ; Chen LL; Chien YW
J Pharm Sci; 2001 Nov; 90(11):1868-77. PubMed ID: 11745744
[TBL] [Abstract][Full Text] [Related]
26. Peculiarities of Pharmacokinetics and Bioavailability of Some Cardiovascular Drugs under Conditions of Antiorthostatic Hypokinesia.
Polyakov AV; Svistunov AA; Kondratenko SN; Kovachevich IV; Repenkova LG; Savelyeva MI; Kukes VG
Bull Exp Biol Med; 2020 Feb; 168(4):465-469. PubMed ID: 32146624
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies.
Venkatesh G; Ramanathan S; Mansor SM; Nair NK; Sattar MA; Croft SL; Navaratnam V
J Pharm Biomed Anal; 2007 Mar; 43(4):1546-51. PubMed ID: 17157469
[TBL] [Abstract][Full Text] [Related]
28. The impact of the site of blood sampling on pharmacokinetic parameters following sublingual dosing to dogs.
Sohlberg E; Halldin MM; Annas A; Königsson K; Jansson B; Pehrson R; Borg N
J Pharmacol Toxicol Methods; 2013; 67(1):1-4. PubMed ID: 23138149
[TBL] [Abstract][Full Text] [Related]
29. [The pharmacokinetics of propranolol when used with the propercuten transdermal therapeutic system (experimental data)].
Piotrovskiĭ VK; Belolipetskaia VG; Vasil'ev AE; Shorr VA; Chichenkov ON; Fel'dshteĭn MM; Metelitsa VI
Eksp Klin Farmakol; 1993; 56(6):53-6. PubMed ID: 8111301
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular and pharmacokinetic consequences of combined administration of verapamil and propranolol in dogs.
Hamann SR; Kaltenborn KE; Vore M; Tan TG; McAllister RG
Am J Cardiol; 1985 Jul; 56(1):147-56. PubMed ID: 4014021
[TBL] [Abstract][Full Text] [Related]
31. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
Pabari RM; McDermott C; Barlow J; Ramtoola Z
Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
[TBL] [Abstract][Full Text] [Related]
32. [Interactions of propranolol with nifedipine, verapamil and diltiazem].
Halawa B; Mazurek W
Pol Tyg Lek; 1988 Oct; 43(44):1412-4. PubMed ID: 3252207
[No Abstract] [Full Text] [Related]
33. [Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration].
Woodcock BG; Wörner P; Rietbrock N; Schwabe L; Frömming KH
Arzneimittelforschung; 1982; 32(12):1567-71. PubMed ID: 6891597
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil.
Berk SI; Beckman K; Hoon TJ; Hariman RJ; Hu D; Siegel FP; Bauman JL
Pharmacotherapy; 1992; 12(1):33-9. PubMed ID: 1549537
[TBL] [Abstract][Full Text] [Related]
35. Same effect of sublingual and oral captopril in hypertensive crisis.
Karakiliç E; Büyükcam F; Kocalar G; Gedik S; Atalar E
Eur Rev Med Pharmacol Sci; 2012 Nov; 16(12):1642-5. PubMed ID: 23161035
[TBL] [Abstract][Full Text] [Related]
36. Site-specific drug delivery in the dog using flexible fiberoptic endoscopy.
Heit MC; Smith DF; Enever RP
J Pharm Sci; 1998 Oct; 87(10):1209-12. PubMed ID: 9758678
[TBL] [Abstract][Full Text] [Related]
37. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness.
Al-Ghananeem AM; Malkawi AH; Crooks PA
Drug Dev Ind Pharm; 2007 May; 33(5):577-82. PubMed ID: 17520450
[TBL] [Abstract][Full Text] [Related]
38. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial.
Angeli P; Chiesa M; Caregaro L; Merkel C; Sacerdoti D; Rondana M; Gatta A
Arch Intern Med; 1991 Apr; 151(4):678-82. PubMed ID: 2012448
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets.
Pereira CM; Tam YK; Coe JY; Olley PM; Collins-Nakai RL
Biopharm Drug Dispos; 1996 Jul; 17(5):365-72. PubMed ID: 8830975
[TBL] [Abstract][Full Text] [Related]
40. Bioavailability of propranolol following oral and transdermal administration in rabbits.
Corbo M; Liu JC; Chien YW
J Pharm Sci; 1990 Jul; 79(7):584-7. PubMed ID: 2398465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
